MacroGenics recently reported strong financial results for the quarter, including a revenue increase and net income boost. The company's focus on B7-H3 assets like vobra duo and MGC026 shows promise for the future. CEO Dr. Scott Koenig highlighted ongoing clinical programs and future prospects.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing